ImageneBio (IMA) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImageneBio (IMA) has outperformed OKYO Pharma (OKYO) over the past year, losing 44.9% versus a loss of 49.5%. OKYO Pharma is the larger company by market cap ($56.2 million vs $48.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMA | OKYO |
|---|---|---|
| Share price | $3.92 | $1.07 |
| Market cap | $48.83M | $56.15M |
| 1-day change | 0.00% | -7.76% |
| YTD return | -43.19% | -48.31% |
| 1-year return | -44.87% | -49.53% |
| 5-year return | -97.86% | — |
| EPS (TTM) | $-2.11 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $800.00K | — |
| Revenue growth (YoY) | -77.14% | — |
| Net income (latest FY) | $-45.35M | $-4.71M |
| Operating margin | -6056.38% | — |
| Net margin | -5668.63% | — |
| 52-week high | $7.60 | $3.20 |
| 52-week low | $3.00 | $1.00 |
| Distance from 52-week high | -48.42% | -66.56% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +359.18% | +678.50% |
| Average volume | 15.86K | 143.41K |
| Shares outstanding | 12.46M | 52.48M |
| Employees | 18 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
IMA vs OKYO FAQ
Which is bigger, ImageneBio or OKYO Pharma?
OKYO Pharma (OKYO) is larger, with a market capitalization of $56.15M compared with $48.83M for ImageneBio (IMA).
Which stock has performed better over the past year, IMA or OKYO?
IMA returned -44.87% over the past 12 months, compared with -49.53% for OKYO (price return, excluding dividends). Past performance does not predict future results.
Are ImageneBio and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.